

RWANDA

Support for Pneumococcal Conjugate Vaccine

This Decision Letter sets out the Programme Terms of a Programme

1. Country:	Rwanda						
2. Vaccine grant number:	18-RWA-12d-A, 19-RWA-12d-A, 20-RWA-12d-A						
3. Date of Decision Letter:	30 September 2019						
4. Date of the Partnership Framework Agreement:	7 June 2013						
5. Programme title:	New Vaccine Support (NVS), Pneumococcal , Routine (Fragility, emergencies and refugees policy)						
6. Vaccine type:	Pneumococcal						
7. Requested product presentation and formulation of vaccine:	PCV13, 4 doses per vial, LIQUID						
8. Programme Duration:¹	2018-2020						
9. Programme Budget (indicative):²	(subject to the terms of the Partnership Framework Agreement, if applicable)						
	2018-2019	2020	2021	2022	2023	2024	Total²
Programme Budget (US\$)	136,127	27,000	-	-	-	-	163,127
10. Vaccine introduction grant	Not applicable						
11. Product switch grant	Not applicable						
12. Indicative Annual Amounts:³	(subject to the terms of the Partnership Framework Agreement, if applicable)						
Type of supplies to be purchased with Gavi funds	2018-2019	2020					
Number of vaccine doses	41,800	8,400					-
Annual Amounts (US\$)	136,127	27,000					-
13. Procurement agency:	UNICEF. The Country shall release its co-financing payments each year to UNICEF.						

¹ This is the entire duration of the programme.

² This is the total amount endorsed by Gavi for the entire duration of the programme.

³ This is the amount that Gavi has approved.

14. Self-procurement:	Not applicable						
15. Co-financing obligations:	Not applicable						
16. Operational support for campaigns:	Not applicable						
17. Additional Reporting Requirements:	<table border="1"> <thead> <tr> <th></th> <th>Due dates</th> </tr> </thead> <tbody> <tr> <td>To prepare for the annual procurement of vaccines, Country shall submit the following information each year: <ul style="list-style-type: none"> Vaccine stock levels including buffer stock Number of children to be vaccinated, wastage rates, any proposed changes in product, presentation or use, or minimum co-financing levels and vaccines received Countries shall report the actual switch date in the first renewal request following the actual implementation. </td> <td>31 March 2020 15 May 2020</td> </tr> <tr> <td>In accordance with applicable Gavi processes, Country shall report on programmatic and financial performance.</td> <td>To be agreed with Gavi Secretariat</td> </tr> </tbody> </table>		Due dates	To prepare for the annual procurement of vaccines, Country shall submit the following information each year: <ul style="list-style-type: none"> Vaccine stock levels including buffer stock Number of children to be vaccinated, wastage rates, any proposed changes in product, presentation or use, or minimum co-financing levels and vaccines received Countries shall report the actual switch date in the first renewal request following the actual implementation. 	31 March 2020 15 May 2020	In accordance with applicable Gavi processes, Country shall report on programmatic and financial performance.	To be agreed with Gavi Secretariat
	Due dates						
To prepare for the annual procurement of vaccines, Country shall submit the following information each year: <ul style="list-style-type: none"> Vaccine stock levels including buffer stock Number of children to be vaccinated, wastage rates, any proposed changes in product, presentation or use, or minimum co-financing levels and vaccines received Countries shall report the actual switch date in the first renewal request following the actual implementation. 	31 March 2020 15 May 2020						
In accordance with applicable Gavi processes, Country shall report on programmatic and financial performance.	To be agreed with Gavi Secretariat						
18. Financial clarifications:	Not applicable						
19. Other conditions:	Not applicable						

Signed by
On behalf of Gavi



Thabani Maphosa
Managing Director, Country Programmes
30 September 2019